Antidepressivos e alterações no peso corporal

Authors

  • Helicínia Giordana Espíndola PEIXOTO Universidade de Brasília
  • Ivana Aragão Lira VASCONCELOS Universidade de Brasília
  • Ana Cláudia Moreira SAMPAIO Secretaria Estadual de Saúde do Distrito Federal
  • Marina Kiyomi ITO Universidade de Brasília

Keywords:

Antidepressant agents, Weight gain, Weight loss, Body weight

Abstract

Depression is a disorder that may affect patient’s weight because of specific factors of the disease, such as changes in appetite and in the level of physical activity, as well as because of the use of antidepressant medications. The objectives of this paper are to analyze studies that discuss the effect of antidepressant medications on the patients’ weight. Medline, Lilacs and Cochrane databases were searched for relevant studies using the words ‘antidepressant’ and ‘weight’. Publications regarding antidepressant drugs commonly used in health services in Brazil and their effects on body weight in depressive patients were selected. The
studies indicated that weight changes related to antidepressant therapies are still controversial, influenced by factors such as length and dosage of antidepressant use, limited power of the studies, among others. Thus, more powerful studies focusing on how antidepressant medications affect weight in depressive patients are still needed.

References

Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJL. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet. 2006; 367(9524): 1747-57.

Meredith LS. Depression: 20 years of progress. Medical Care. 2004; 42(6):499-501.

Andrade L, Walters EE, Gentil V, Laurenti R. Prevalence of ICD-10 mental disorders in a catchment area in the city of São Paulo, Brazil. Soc Psychiatry Psychiatr Epidemiol. 2002; 37(7): 316-25.

Versiani M. Depressão uma doença crônica. Ciência Hoje. 2004; 34(201):34-7.

Michelson D, Amsterdam JD, Quitkin FM, Reimherr FW, Rosenbaum JF, Zajecka J, et al. Changes in weight during a 1- year trial of fluoxetine. Am J Psychiatry. 1999; 156(8):1170-6.

Dixon JB, Dixon ME, O´Brien PE. Depression in association with severe obesity: changes with weight loss. Arch Intern Med. 2003; 163(17): 2058-65.

Gopalaswamy AK, Morgan R. Too many chronically mentally disabled patients are too fat. Acta Psychiatr Scand. 1985; 72(3):254-8.

Aronne LJ, Segal KR. Weight gain in the treatment of mood disorders. J Clin Psychiatry. 2003; 64(8):22-9.

Virk S, Schwartz TL, Jindal S, Nihalani N, Jones N. Psychiatric medication induced obesity: an aetiology review. Obes Rev. 2004; 5(3):167-70.

World Health Organization. Diet, nutrition, and the prevention of chronic diseases. Report of join WHO/FAO expert consultation. WHO Technical Report Series. Geneva; 2003. [cited 2007 Jan]. Available from: <http://whqlibdoc.who.int/trs/WHO_TRS_916.pdf>.

Li Z, Maglione M, Tu W, Mojica W, Arterburn D, Shugarman LR, et al. Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med. 2005; 142(7):532-46.

Consenso Latinoamericano de Obesidad. Rio de Janeiro, 1998 [aceso 2006 jun]. Disponible en: <http://www.abeso.org.br/downloads.htm>.

Sociedade Brasileira de Diabetes. Consenso Brasileiro sobre Diabetes 2002: diagnóstico e classificação do diabetes melito e tratamento do diabetes melito do tipo 2. Rio de Janeiro: Diagraphic; 2003.

Carek OJ, Dickerson LM. Current concepts in the pharmacological management of obesity. Drugs. 1999; 57(6):883-904.

Foltin RW, Comer SD, Fishman MW. Effect of fluoxetine on food intake of humans living in residential laboratory. Appetite. 1996; 27(2): 165-81.

Bernstein JG. Induction of obesity by psychotropic drugs. Ann NY Acad Sci. 1987; 499: 203-15.

Weber E, Stack J, Pollock BG, Mulsant B, Begley A, Mazumdar S, et al. Weight change in older depressed patients during acute pharmacotherapy with paroxetine and nortriptyline. Am J Geriatr Psychiatry. 2000; 8(3):245-50.

Hinze-Selch D, Schuld A, Kraus T, Kuhn M, Uhr M, Haack M, et al. Effects of antidepressants on weight and on the plasma levels of leptin, TNf-alfa and soluble TNF receptors: a longitudinal study in patients treated with amitriptyline or paroxetine. Neuropsychopharmacology. 2000; 23(1):13-9.

Kupfer DJ, Coble PA, Rubinstein D. Changes in weight during treatment for depression. Psychosom Med. 1979; 41(7):535-44.

Frank E, Kupfer DJ, Bulik CM, Leveson, JA. Imipramine and weight gain during the treatment of recurrent depression. J Affect Disord. 1990; 20(3):165-72.

Marques CS, Nardi AE, Figueira I, Mendlowicz M, Coscarelli P, Andrade Y, et al. Inibidores seletivos de recaptação de serotonina (ISRS) e ganho de peso. J Bras Psiq. 1996; 45(2):111-4.

Luis DA, Luis J, Aller R, Romero E. Modificación del patrón de ingesta en pacientes obesos tratados con paroxetina. Nutr Hosp. 2001; 16(1):19-22.

Fava M, Judge R, Hooq SL, Nilsson ME, Koke SC. Fluoxetine versus sertralline and paroxetine in major depressive disorder: changes in weight with long-term treatment. J Clin Psychiatry. 2000; 61(11): 863-7.

Chouinard G. Bupropion and amitriptyline in the treatment of depressed patients. J Clin Psychiatry. 1983; 44(5 pt 2):121-9.

Hecht Orzack M, Cole JO, Friedman L, Bird M, McEachern J. Weight changes in antidepressants: a comparison of amitriptyline and trazodone. Neuropsychobiology. 1986; 15(Suppl 1):28-30.

Montgomery SA, Reimitz PE, Zivkov M. Mirtazapine versus amitriptyline in the long-term treatment of depression: a double-blind placebo-controlled study. Int Clin Psychopharmacol. 1998; 13(2): 63-73.

Nelson JC, Pritchett YL, Martynow O, Yu JY, Mallinckrodt CH, Detke MJ. The safety and tolerability of duloxetine compared with paroxetine and placebo: a pooled analysis of four clinical trials. Prim Care Companion J Clin Psychiatry. 2006; 8(4):212-9.

Frank E, Kupfer DJ, Buhari A, McEachran AB, Grochocinski VJ. Imipramine and weight gain during the long-term treatment of recurrent depression. J Affect Disord. 1992; 26(1):65-72.

Kazes M, Danion JM, Grangé D, Pradignac A, Simon Ch, Burrus-Mehl F, et al. Eating behaviour and depression before and after antidepressant treatment: a prospective, naturalistic study. J Affect Disord. 1994; 30(3):193-207.

Deitos TFH, Silva LG, Alves ACA. Depressão, obesidade e fluoxetina. J Bras Psiq. 1995; 44(10): 529-32.

Dugan DJ. Antidepressants: using pharmacology to individualize therapy. J Pharm Pract. 2001; 14(6): 458-66.

Moreno RA, Moreno DH, Soares MBM. Psicofarmacologia de antidepressivos. Rev Bras Psiquiatr. 1999; 21(1):24-40.

Peretti S, Judge R, Hindmarch I. Safety and tolerability considerations: tricyclic antidepressants vs selective serotonin reuptake inhibitors. Acta Psychiatr Scand Suppl. 2000; 101(403):17-25.

Rockwell WJK. Psychotropic drugs promoting weight gain: health risks and treatment implications. South Med J. 1983; 76(11):1407-12.

Rosenzweig-Lipson S, Beyer CE, Hughes ZA. Differentiating antidepressants of the future: efficacy and safety. Pharmacol Ther. 2007, 113(1): 134-53.

Downloads

Published

2023-09-04

How to Cite

Espíndola PEIXOTO, H. G., Aragão Lira VASCONCELOS, I., Moreira SAMPAIO, A. C. ., & Kiyomi ITO, M. . (2023). Antidepressivos e alterações no peso corporal. Brazilian Journal of Nutrition, 21(3). Retrieved from https://seer.sis.puc-campinas.edu.br/nutricao/article/view/9589

Issue

Vol. 21 No. 3 (2008): Revista de Nutrição

Section

Comunicação

License

Copyright (c) 2023 Helicínia Giordana Espíndola PEIXOTO, Ivana Aragão Lira VASCONCELOS, Ana Cláudia Moreira SAMPAIO, Marina Kiyomi ITO

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.